Recent News

• 02.10.2026 - Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
• 02.10.2026 - Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization
• 02.02.2026 - Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
• 01.21.2026 - Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year
• 01.08.2026 - Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026
• 01.06.2026 - Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium
• 01.05.2026 - Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan
• 12.19.2025 - Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
• 11.11.2025 - Quest Diagnostics Declares Quarterly Cash Dividend

Recent Filings

• 02.10.2026 - 8-K Current report
• 02.10.2026 - EX-99.1 EX-99.1
• 02.10.2026 - 144 Report of proposed sale of securities
• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 11.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - 144 Report of proposed sale of securities
• 11.25.2025 - 144 Report of proposed sale of securities
• 11.20.2025 - 4 Statement of changes in beneficial ownership of securities